Skip to Content

Akari Therapeutics PLC ADR AKTX

Morningstar Rating
$3.16 +0.11 (3.61%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AKTX is trading at a 672% premium.
Price
$3.03
Fair Value
$9.43
Uncertainty
Extreme
1-Star Price
$241.88
5-Star Price
$3.41
Economic Moat
Pywg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AKTX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.05
Day Range
$2.983.29
52-Week Range
$1.085.50
Bid/Ask
$3.10 / $3.29
Market Cap
$37.10 Mil
Volume/Avg
10,424 / 23,728

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
12

Valuation

Metric
AKTX
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
AKTX
Quick Ratio
0.21
Current Ratio
0.44
Interest Coverage
Quick Ratio
AKTX

Profitability

Metric
AKTX
Return on Assets (Normalized)
−381.06%
Return on Equity (Normalized)
−1,849.42%
Return on Invested Capital (Normalized)
−1,859.07%
Return on Assets
AKTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LjktlmmnNndwss$123.6 Bil
Regeneron Pharmaceuticals Inc
REGN
XtkpycwrXtflc$113.1 Bil
Moderna Inc
MRNA
BfbsxhvSgz$55.7 Bil
BioNTech SE ADR
BNTX
GfgxmhnfPzs$23.1 Bil
argenx SE ADR
ARGX
CzzjkgkkBywm$22.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
XdbspzrcMyvrq$20.2 Bil
Biomarin Pharmaceutical Inc
BMRN
SjnyftrlTnjyncg$16.0 Bil
United Therapeutics Corp
UTHR
GmpldqbbCmbqr$12.8 Bil
Incyte Corp
INCY
MqmlnztHjskcmv$12.3 Bil
Royalty Pharma PLC Class A
RPRX
HssgfqqzsThhjwd$12.3 Bil

Sponsor Center